Practical use of Anticoagulants

  • Robert M. Lindsay
  • Anne M. Smith

Abstract

To use anticoagulants optimally during dialysis it is necessary to understand hemostasis, how to evaluate it and how therapeutic agents interfere with it. Knowledge of the hemostatic defects found in uremia and the influence of dialysis upon these is necessary, as is an understanding of foreign surface induced coagulation. This chapter presents such information before providing a practical guide to anticoagulant use.

Keywords

Platelet Aggregation International Normalize Ratio Activate Partial Thromboplastin Time Thrombolytic Agent Heparin Dosage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jandl JH: Blood: Textbook of Hematology. Boston, Toronto, Little, Brown, and Co, 1987Google Scholar
  2. 2.
    Ratnoff O, Forbes CD: Disorders of Hemostasis. Orlando Grune and Stratton Ine, 1984Google Scholar
  3. 3.
    Schumacher HR, Garvin DF, Triplett DA: Introduction to Laboratory Hematology and Hematopathology. New York, Alan R. Liss Ine, 1984Google Scholar
  4. 4.
    Dacie Sir JV, Lewis SM: Practical Haematology. 6th edition, Edinburgh, Churchill Livingstone, 1984Google Scholar
  5. 5.
    Hirsh J: Venous Thromboembolism: Guide to Management. Missisauga, Ontario, DuPont Pharmaceuticals, 1986Google Scholar
  6. 6.
    Lee GR, Boggs DR, Bithell TC, Foerster J, Athene JW, Lubene JN: Clinical Hematology. Philadelphia, Lea and Febiger, 1981Google Scholar
  7. 7.
    Bowie EJW, Owen CA Jr: Standardisation of the bleeding time. Scand J Haematol 25 (Suppl 37): 87, 1980Google Scholar
  8. 8.
    Jorpes JE: Heparin in the Treatment of Thrombosis. An Account of its Chemistry, Physiology and Application in Medicine, London, Oxford University Press, 1946Google Scholar
  9. 9.
    Cifonelli JA, King J: Structural studies on heparins with unusually high N-acetylglucosamine contents. Biochim Biophys Acta 320: 331, 1973PubMedGoogle Scholar
  10. 10.
    Rosenberg RD, Lam LH: Heparinized surface - a comment. Ann NY Acad Sci 283: 404, 1977Google Scholar
  11. 11.
    O’Reilly RA: Anticoagulant, antithrombotic and thrombolytic drugs, in The Pharmacological Basis of Therapeutics, edited by Gilman AG, Goodman LS, Gilman A, 6th edition, New York, MacMillan Publishing Co, 1980Google Scholar
  12. 12.
    Wessler S, Gitel S: Control of heparin therapy. Prog Hemost Thromb 3: 311, 1976PubMedGoogle Scholar
  13. 13.
    King DJ, Kelton JG: Heparin-associated thrombocytopenia. Ann Intern Med 100: 535, 1984PubMedGoogle Scholar
  14. 14.
    Best CH: Heparin and thrombosis. Br Med J 2: 977, 1938PubMedGoogle Scholar
  15. 15.
    Moolten SE, Vroman L, Vroman GMS: Role of blood platelets in thromboembolism. Arch Intern Med 84: 667, 1949Google Scholar
  16. 16.
    O’Brien JR, Shoobridge SM, Finch WJ: Comparison of the effect of heparin and citrate on platelet aggregation. J Clin Path 22, 1969Google Scholar
  17. 17.
    Bowie EJW, Owen CA, Thompson JH: A test of platelet adhesiveness. Mayo Clin Proc 44: 306, 1969PubMedGoogle Scholar
  18. 18.
    Salzman EW: Measurement of platelet adhesiveness. A simple in vitro technique demonstrating an abnormality in von Willebrand’s disease. J Lab Clin Med 62: 724, 1963PubMedGoogle Scholar
  19. 19.
    Thomson C, Forbes CD, Prentice CR: The potentiation of platelet aggregation by heparin in vitro and in vivo. Clin Sci Mol Med 45: 485, 1973PubMedGoogle Scholar
  20. 20.
    Lindsay RM, Prentice CRM, Ferguson D, Muir WM, McNicol GP: A method for the measurement of platelet adhesiveness by use of dialysis membranes in a test-cell. Br J Haematol 24: 377, 1973PubMedGoogle Scholar
  21. 21.
    Lindsay RM, Rourke JTB, Reid BD, Linton AL, Gilchrist T, Courtney J, Edwards RO: The role of heparin on platelet retention by acrylonitrile co-polymer dialysis membranes. J Lab Clin Med 89: 4, 1977Google Scholar
  22. 22.
    Loeliger EA: ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Acta Haematol (Basel) 72: 405, 1984PubMedGoogle Scholar
  23. 23.
    Barrow DA, Maynard JR: Standardisation of the prothrombin time for monitoring oral anticoagulant therapy: the international normalised ratio. Dade Coagulation Technical Bulletin #19, 1987Google Scholar
  24. 24.
    Sherry S, Bell WR, Duckert H, Fletcher P, Gurewich V, Marder VJ, Roberts H, Salzman EW, Sasahara A, Verstraete M: Thrombolytic therapy in thrombosis: a National Institutes of Health Consensus Development Conference. Ann intern Med 93: 141, 1980Google Scholar
  25. 25.
    Bell WR, Meek AG: Guidelines for the use of thrombolytic agents. N Engl J Med 301: 1266, 1979PubMedGoogle Scholar
  26. 26.
    Marder VJ: The use of thrombolytic agents: choice of patient drug administration, laboratory monitoring. Ann Intern Med 90: 802, 1979PubMedGoogle Scholar
  27. 27.
    Macfarlane RG, Pilling J: Fibrinolytic activity of normal urine. Nature 159: 779, 1947PubMedGoogle Scholar
  28. 28.
    Williams JRB: The fibrinolytic activity of urine. Br J Exp Pathol 32: 530, 1951PubMedGoogle Scholar
  29. 29.
    Sobel GW, Möhler SR, Jones NW, Dowdy AB, Guest MM: Urokinase: an activator of plasma Profibrinolysin extracted from urine. Am J Physiol 171: 768, 1952Google Scholar
  30. 30.
    Thorsen S, Glas-Greenwalt P, Astrup T: Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thromb Diath Haemorrh 28: 65, 1972PubMedGoogle Scholar
  31. 31.
    Risius B, Graor RA, Geisinger MA, Zelch MG, Lucas FV, Young JR, Grossbard EB: Recombinant human tissue-type plasminogen activator for thrombolysis in peripheral arteries and bypass grafts. Radiology 160: 183, 1986PubMedGoogle Scholar
  32. 32.
    Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA, Ludbrook PA, Yasuda I, Bulkley BH, Robison AK, Hutter AM Jr, Bell WR, Spadaro JJ Jr, Khaw BA, Grossbard EB: Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 70: 1012, 1984PubMedGoogle Scholar
  33. 33.
    Moncada S, Gryglewski R, Bunting S, Vane JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663, 1976PubMedGoogle Scholar
  34. 34.
    Johnson RA, Morton DR, Kinner JH, Gorman RR, McGuire JC, Sun FF, Whitaker N, Bunting S, Salman J, Moncada S, Vane JR: The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 12: 915, 1976PubMedGoogle Scholar
  35. 35.
    Moncada S, Herman AG, Higgs EA, Vane JR: Differential formation of prostacyclin (PGx or PGI2) by layers of the arterial wall: An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res 11: 323, 1977PubMedGoogle Scholar
  36. 36.
    Maclntyre DE, Pearson JD, Gordon JL: Localisation and stimulation of prostacyclin production in vascular cells. Nature 271: 549, 1978Google Scholar
  37. 37.
    Armstrong JN, Lattimer N, Moncada S, Vane JR: Comparison of the vasodepressor effects of prostacyclin and 6-oxyl-prostaglandin F1 alpha with those of prostaglandin E2 in rats and rabbits. Br J Pharmacol 62: 125, 1978PubMedGoogle Scholar
  38. 38.
    Cazenave JP, Dejana E, Kinlough-Rathbone RL, Richardson M, Packham MA, Mustard JF: Prostaglandins I2 and E1 reduce rabbit and human platelet adherence without inhibiting serotonin release from adherent platelets. Thromb Res 15: 273, 1979PubMedGoogle Scholar
  39. 39.
    Higgs EA, Moncada S, Vane JR, Caen JP, Michel H, Tobelem G: Effect of prostacyclin (PGI2) and platelet adhesion to rabbit arterial subendothelium. Prostaglandins 16: 17, 1978PubMedGoogle Scholar
  40. 40.
    Weiss HJ, Turitto VT: Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium. Blood 53: 244, 1979PubMedGoogle Scholar
  41. 41.
    Higgs EA, Higgs GA, Moncada S, Vane JR: Prostacyclin (PGI2) inhibits the formation of platelet thrombi in arterioles and venules of the hamster cheek pouch. Br J Pharmacol 63: 535, 1978PubMedGoogle Scholar
  42. 42.
    Aspirin and other antiplatelet drugs in the prophylaxis of thrombosis. Blood Rev 1: 9, 1987Google Scholar
  43. 43.
    Goodnight SH, Harris WS, Connor WE: The effects of dietary W3 fatty acids on platelet composition and function in man. A prospective controlled study. Blood 58: 880, 1981PubMedGoogle Scholar
  44. 44.
    Fuster V, Chesebro JH: Series on pharmacology in practice. 10. Anti-thrombotic therapy: role of platelet-inhibitor drugs. 11. Pharmacological effects of platelet-inhibitor drugs. Mayo Clin Proc 56: 185, 1981PubMedGoogle Scholar
  45. 45.
    Harker LA, Slichter SJ: Platelet and fibrinogen consumption in man. N Engl J Med 287: 999, 1972PubMedGoogle Scholar
  46. 46.
    Harker LA: In vivo evaluation of antithrombotic therapy in man. Thromb Diath Haemorrh (suppl 60): 481, 1974Google Scholar
  47. 47.
    Moncada S, Korbut R: Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1: 1286, 1978PubMedGoogle Scholar
  48. 48.
    Riesman D: Hemorrhages in the course of Bright’s disease with a nephrotic origin. Am J Med Sci 134: 709, 1907Google Scholar
  49. 49.
    Donner L, Neuwirtova: The hemostatic defect of acute and chronic uraemia. Thromb Diath Haemorrh 5: 319, 1960PubMedGoogle Scholar
  50. 50.
    Rabiner SF: Uremic bleeding. Prog Hemost Thromb 1: 233, 1972PubMedGoogle Scholar
  51. 51.
    Castaldi PA, Rosenberg MC, Stewart JH: The bleeding disorder of uraemia. Lancet 2: 66, 1966PubMedGoogle Scholar
  52. 52.
    Salzman EW, Neri LL: Adhesiveness of blood platelets in uremia. Thromb Diath Haemorrh 15: 84, 1966PubMedGoogle Scholar
  53. 53.
    George CRP, Slichter SJ, Quadracci LJ, Striker GE, Harker LA: A kinetic evaluation of hemostasis in renal disease. N Engl J Med 291: 1111, 1974PubMedGoogle Scholar
  54. 54.
    Stewart JH, Castaldi PA: Uraemic bleeding: A reversible platelet defect corrected by dialysis. Q J Med 36: 409, 1967PubMedGoogle Scholar
  55. 55.
    Rabiner SF, Hrodek O: Platelet factor 3 in normal subjects and patients with renal failure. J Clin Invest 47: 901, 1968PubMedGoogle Scholar
  56. 56.
    Joist JH, Pechan J, Schikowski U, Hubner G, Gross R: Studies on the nature and etiology of uremic thrombocytopathy. Verh Dtsch Ges Inn Med 75: 476, 1969PubMedGoogle Scholar
  57. 57.
    Lindsay RM, Moorthy AV, Koens F, Linton AL: Platelet function in dialyzed and non-dialyzed patients with chronic renal failure. Clin Nephrol 4: 52, 1975PubMedGoogle Scholar
  58. 58.
    Lindsay RM, Friesen M, Koens F, Linton AL, Oreopoulos D, DeVeber G: Platelet function in patients on long term peritoneal dialysis. Clin Nephrol 6: 335, 1976PubMedGoogle Scholar
  59. 59.
    Lindsay RM, Friesen M, Aronstam A, Andrus F, Clark WF, Linton AL: Improvement of platelet function by increased frequency of hemodialysis Clin Nephrol 10: 67, 1978PubMedGoogle Scholar
  60. 60.
    Nenci GG, Berrettini M, Agnelli G, Parise P, Buoncristiani U, Ballatori E: Effect of peritoneal dialysis, haemodialysis and kidney transplantation on blood platelet function. I. Platelet aggregation by ADP and epinephrine. Nephron 23: 287, 1979PubMedGoogle Scholar
  61. 61.
    Jorgenson KA, Ingeberg S: Platelets and platelet function in patients with chronic ureamia on maintenance hemodialysis. Nephron 23: 233, 1979Google Scholar
  62. 62.
    Kazatchkine M, Sultan Y, Caen JP, Bariety J: Bleeding in renal failure: a possible cause. Br Med J 2: 612, 1976PubMedGoogle Scholar
  63. 63.
    Remuzzi G, Pusineri F: Coagulation defects in uremia. Kidney Int 33 (Suppl 24): S123, 1988Google Scholar
  64. 64.
    Remuzzi G, Livio M, Cavenaghi AE, Marchesi D, Mecca G, Donati MB, de Gaetano G: Unbalanced prostaglandin synthesis and plasma factors in uraemic bleeding a hypothesis. Thromb Res 13: 531, 1978PubMedGoogle Scholar
  65. 65.
    Di Minno G, Martinez J, McKean ML, De La Rosa J, Burke JF, Murphy S: Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 79: 552, 1985PubMedGoogle Scholar
  66. 66.
    Duke WW: The relation of blood platelets to hemorrhagic disease. JAMA 60: 1185, 1910Google Scholar
  67. 67.
    Livio M, Gotti E, Marchesi D, Mecca G, Remuzzi G, De Gaetano G: Uremic bleeding: role of anemia and beneficial effect of red cell transfusions. Lancet 2: 1013, 1982PubMedGoogle Scholar
  68. 68.
    Fernandez F, Goudable C, Sie P, Ton-That H, Durand D, Sue JM, Boneu B: Low hematocrit and prolonged bleeding time in uremic patients: effect of red cell transfusions. Br J Hematol 59: 139, 1985Google Scholar
  69. 69.
    Moia M, Vizzotto L, Cattaneo M, Mannucci PM, Cassati S, Pontichelli C: Improvement in the hemostatic defect of uremia after treatment with recombitant human erythropoeitin. Lancet 2: 1127, 1987Google Scholar
  70. 70.
    Brash JL, Lyman DJ: Adsorption of proteins and lipids to non-biological surfaces, in The Chemistry of Biosurfaces, edited by Hair ML, New York, Marcel Dekker Inc, 1971, p 177Google Scholar
  71. 71.
    Salzman EW: Role of platelets in blood-surface interactions. Fee Proc 30: 1503, 1971Google Scholar
  72. 72.
    Vroman L, Adams AL, Klings M: Interactions among human blood proteins at interfaces. Fed Proc 30: 1494, 1971PubMedGoogle Scholar
  73. 73.
    Feijen J: Thrombogenesis caused by blood-foreign surface interaction, in Artificial Organs, edited by Kenedi RM, Courtney JM, Gaylor JDS, Gilchrist T, Baltimore, Univ Park Press, 1976, p 235Google Scholar
  74. 74.
    Niemetz J, Muhlfelder T, Chierego ME, Troy B: Procoagulant activity of leukocytes. Ann NY Acad Sci 283: 208, 1977Google Scholar
  75. 75.
    Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS: Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 296: 769, 1977PubMedGoogle Scholar
  76. 76.
    Jacob HS, Craddock PR, Hammerschmidt DE, Moldow DF: Complement-induced granulocyte aggregation: an unsuspected mechanism of disease. N Engl J Med 302: 89, 1980Google Scholar
  77. 77.
    Lindsay RM, Prentice CRM, Davidson JF, Burton JA, McNicol GP: Haemostatic changes during dialysis associated with the thrombus formation on dialysis membranes. Br Med J 4: 454, 1972PubMedGoogle Scholar
  78. 78.
    Lindsay RM, Ferguson D, Prentice CRM, Burton JA, McNicol GP: Reduction of thrombus formation on dialyzer membranes by aspirin and RA233. Lancet 2: 1287, 1972PubMedGoogle Scholar
  79. 79.
    Lindsay RM, Rourke J, Reid B, Friesen M, Linton AL, Courtney J, Gilchrist T: Platelets, foreign surfaces and heparin. Trans Am Soc Artif Intern Organs 22: 292, 1976PubMedGoogle Scholar
  80. 80.
    Wilkinson R, Lindsay RM, Burton JA: The membrane support system and thrombus formation on dialysis membranes. Proc Eur Dial Transplant Assoc 10: 306, 1973PubMedGoogle Scholar
  81. 81.
    Gotch FA, Keen ML: Precise control of minimal heparinization for high bleeding risk hemodialysis. Trans Am Soc Artif Intern Organs 23: 168, 1977PubMedGoogle Scholar
  82. 82.
    Harada K, Zucker MB: Simultaneous development of PF4 activity and release of 14C-serotonin. Thromb Diath Haemorrh 25: 41, 1971PubMedGoogle Scholar
  83. 83.
    Rucinski B, Niewiarowski J, James P, Walz DA, Budzynski AZ: Antiheparin proteins secreted by human platelets: purification, characterization, and radioimmunoassay. Blood 53: 47, 1979PubMedGoogle Scholar
  84. 84.
    O’Brien JR: Antithrombin III and heparin clotting times in atherosclerosis and thrombosis. Thromb Diath Haemorrh 32: 116, 1974PubMedGoogle Scholar
  85. 85.
    Aronstam A, Dennis B, Friesen MJ, Clark WF, Linton AL, Lindsay RM: Heparin neutralizing activity in patients with renal disease on maintenance haemodialysis. Thromb Diath Haemorrh 35: 695, 1978Google Scholar
  86. 86.
    Woods HF, Ash G, Weston MJ, Bunting S, Moncada S, Vane JR: Prostacyclin can replace heparin in haemodialysis in dogs. Lancet 2: 1075, 1978PubMedGoogle Scholar
  87. 87.
    Turney JH, Fewell MR, Williams LC, Parsons V, Weston MH: Platelet protection and heparin sparing with prostacylin regular dialysis therapy. Lancet 2: 219, 1980PubMedGoogle Scholar
  88. 88.
    Zusman RM, Rubin RH, Cato AE, Cocchetto DM, Crow JW, Tolkoff-Rubin N: Haemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 304: 934, 1981PubMedGoogle Scholar
  89. 89.
    Rylance PB, Gordge MP, Ireland H, Lane DA, Weston MJ: Haemodialysis with prostacyclin (Epoprostenol) alone Proc Eur Dial Transplant Assoc Eur Renal Assoc 21: 281, 1984Google Scholar
  90. 90.
    Lindsay RM: Variable heparin requirements during hemodialysis-Why? asaio J 3: 81, 1980Google Scholar
  91. 91.
    Glaser P, Guedsder R, Rouby J, Eurin VB: Hemodialysis without heparin is possible. Lancet 1: 579, 1979Google Scholar
  92. 92.
    Sanders PW, Taylor H, Curtis J: Hemodialysis without anticoagulation. Am J Kidney Dis 5: 32, 1985PubMedGoogle Scholar
  93. 93.
    Schwab SJ, Onorato JJ, Sharar LR, Dennis PA: Hemodialysis without anticoagulation: 1 year prospective trial in hospitalized patients at risk for bleeding. Am J Med 83: 405, 1987PubMedGoogle Scholar
  94. 94.
    Caruana RJ, Raiai RM, Bush JV, Kramer MS, Goldstein SJ: Heparin free dialysis: comparative data and results in high risk patients. Kidney Int 31: 1351, 1987PubMedGoogle Scholar
  95. 95.
    Hall GH, Holman HM, Webster ADB: Anticoagulation by ancrod for haemodialysis. Br Med J 4: 591, 1970PubMedGoogle Scholar
  96. 96.
    Pinnick RV, Wiegmann TB, Diederich DA: Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Engl J Med 308: 258, 1983PubMedGoogle Scholar
  97. 97.
    von Brecht JH, Flanigan MJ, Freeman RM, Lim VS: Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. Am J Kidney Dis 8: 196, 1986Google Scholar
  98. 98.
    Kelleher SO, Schulman G: Severe metabolic alkalosis complicated regional citrate hemodialysis. Am J Kidney Dis 9: 235, 1987PubMedGoogle Scholar
  99. 99.
    Flanigan MJ, von Brecht J, Freeman RM, Lim VS: Reducing the hemorrhagic complications of HD: a controlled comparison of low dose citrate anticoagulation. Am J Kidney Dis 9: 147, 1987PubMedGoogle Scholar
  100. 100.
    Kaedi A, Pinio GF, Shimizu A, Drivedi H, Hirsch J, Gent M: Arteriovenous shunt thrombosis: Prevention by sulfinpyrazone. N Engl J Med 290: 304, 1974Google Scholar
  101. 101.
    Harter HR, Burch JW, MajerusPW, Stanford N, Delmez JA, Anderson CB, Weerts CA: Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med 301: 577, 1979PubMedGoogle Scholar
  102. 102.
    Wing AJ, Curtis JR, de Wardener HE: Reduction of clotting in Scribner shunts by long-term anticoagulation. Br Med J 3: 143, 1976Google Scholar
  103. 103.
    Clagett GP, Russo M, Hufnagel H: Platelet changes after placement of aortic prostheses in dogs. I. Biochemical and functional alterations. J Lab Clin Med 97: 345, 1981PubMedGoogle Scholar
  104. 104.
    Harker LA, Slichter S, Sauvage LR: Platelet consumption by arterial prostheses: The effects of endothelialization and pharmocologic inhibition of platelet function. Ann Surg 186: 594, 1977PubMedGoogle Scholar
  105. 105.
    Oblath RW, Buckley FO, Green RM, Schwartz SI, DeWeese J A: Prevention of platelet aggregation and adherence to prosthetic vascular grafts by aspirin and dipyridamole. Surgery 84: 37, 1978PubMedGoogle Scholar
  106. 106.
    Clunie GJA, Martin AM, Nolan B: Intermittent haemodialysis: insertion and care of the Silastic Teflon cannula. Br Med J 3(Suppl July–Sept): 88, 1967PubMedGoogle Scholar
  107. 107.
    Anderson DC, Martin AN, Clunie GJA, Stewart WK, Robson AS: The use of streptokinase in the declotting of arteriovenous shunts. Proc Eur Dial Transplant Assoc 4: 55, 1967Google Scholar
  108. 108.
    Watt DL, Dun BP, Livingston WR, MacDougall Al, MacKay RKS, Obineche EN, Rennie JB: The use of urokinase in declotting arteriovenous shunts. Proc Eur Dial Transplant Assoc 6: 88, 1969Google Scholar
  109. 109.
    Mcintosh CS, Petrie JC, MacLeod N: Maintenance of SilasticTeflon shunts for intermittent haemodialysis. Br Med J 4: 717, 1969PubMedGoogle Scholar
  110. 110.
    Clunie GJA, Hartley L: Treatment of clotting in external-arteriovenous shunts with a fibrinolytic enzyme. Med J Aust 2: 463, 1969Google Scholar
  111. 111.
    Larm O, Larsson R, Olsson P: A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomat Med Devices Artif Organs 11: (2 and 3), 1984Google Scholar
  112. 112.
    Lindsay RM, Mason R, Kim SW, Andrade JD, Hawkin RM: Blood surface interactions. Trans Am Soc Artif Intern Organs 26: 603, 1980PubMedGoogle Scholar
  113. 113.
    ten Cate H, Henny CP, ten Cate JW, Buller HR, Mooy MC, Surachno S, Wilmink JM: Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and dialysis patients. Thromb Res 39: 211, 1985PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • Robert M. Lindsay
  • Anne M. Smith

There are no affiliations available

Personalised recommendations